Compare Viatris Inc (VTRS) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Workiva Inc — how do they compare? Viatris Inc trades at $17.58 (market cap $19.79B), while Workiva Inc trades at $55.02 (market cap $3.21B). The key difference: Viatris Inc is far larger — about 6.2× Workiva Inc's market cap, and Viatris Inc pays a 2.83% dividend while Workiva Inc pays none. Which is the better fit depends on your goals.
| VTRS | WK | |
|---|---|---|
Market Cap | $19.79B | $3.21B |
Sector | Health | Technology |
52-Week High | $17.39 | $93.31 |
52-Week Low | $8.74 | $44.31 |
Enterprise Value | $32.00B | $3.14B |
Dividend Yield | 2.83% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
